MI-EATON
9.3.2023 12:31:42 CET | Business Wire | Press release
Intelligent power management company Eaton today announced it will be displaying its line of power connectors and terminals for electrified and internal combustion construction and off-highway vehicles at the CONEXPO-CON/AGG construction trade show March 14-18 in Las Vegas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005192/en/
Royal Power Solutions large LP12, LP16 and RD14 terminals are designed for vehicles typically used in construction and off-highway fields. (Photo: Business Wire)
The connectors were designed and developed by Royal Power Solutions (RPS), which Eaton acquired in 2022. Established in 1938, RPS is a global leader in the development and production of critical high-precision power- and signal-distribution terminals and connectors.
“The construction industry, like many others, is transitioning to electrification. Eaton’s global and diverse footprint has broadened our reach and ability to grow in this market,” said Chris Mancuso, general manager, Power Connections, Eaton’s eMobility business. “As the construction industry electrifies, the need for differentiating terminals and connectors evolves in parallel. We have seen a similar transition in the automotive market.”
Eaton’s portfolio of industry-leading electrical solutions includes terminals, connectors and other electrical components designed to handle current levels up to 500 amps. Among those components are stamped battery and eyelet terminals that can withstand vibration and harsh environments, making them ideal for commercial and off-highway vehicles.
High Power Lock Box connectors provide protection, superior performance
Eaton’s high power lock box (HPLB) power connectors are ideal for current and future electrified construction and off-highway vehicle solutions and can help reduce common warranty issues. The HPLB connectors offer a space-saving profile, superior performance, cost savings and reduced manufacturing complexity. The HPLB terminals provide efficiency, reliability and have stronger current carrying capabilities compared to terminals on the market today.
The HPLB terminal system forms a connection in a unique way that provides improved contact force as the temperature increases. Unlike traditional competitors’ box-and-blade or pin-and-socket terminal connections, Eaton’s HPLB terminals use an inverted contact system approach for a stronger connection.
Terminals designed for construction, aggregate industries
Part of the HPLB product line, the low-profile 12 (LP12), low-profile 16 (LP16) and round 14 (RD14) terminals are larger and designed for vehicles typically used in construction and agricultural fields. Able to carry up to 500 amps, the HPLB terminals allow global customers to simplify the manufacturing process and open new areas of opportunity for electrified off-highway vehicles.
Busbars feature low profile, flexibility to meet design requirements
Another technology now available to Eaton’s construction and off-highway vehicle customers is RigiFlex™ busbars, which can be manufactured in copper or aluminum, depending on customer requirements. With a unique, simple, single piece flow manufacturing process, Eaton can scale volume to meet any customer specification.
The RigiFlex™ busbar is rigid in some areas, but flexible in sections that require expansion, contraction or elevated changes in the system design. This flexibility also works well across the battery pack in areas that need to comply with expansion and contraction during charging and discharging cycles due to changing cell thicknesses.
Low-profile busbars enable space-efficient design without heat sinks for weight savings. Eaton also can produce busbars with a level of flatness over length unmatched by competitors.
“When off-highway equipment is assembled, it’s largely done manually since robots have difficulty handling round wires, which are hard for them to grasp,” Mancuso said. “When employing high power lock box terminals our Rigiflex™ busbars improve the assembly process, safety and time to complete the manufacturing process and with less equipment and fewer assembly personnel.”
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005192/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
